Restoration of chemosensitivity by bortezomib: implications for refractory myeloma

Nat Rev Clin Oncol. 2009 Apr;6(4):237-40. doi: 10.1038/nrclinonc.2009.15.

Abstract

Background: A 59-year-old woman presented to the emergency department with a left rib fracture and was diagnosed with IgA multiple myeloma. The patient underwent autologous bone-marrow transplantation, and 14 months later she developed obstructive jaundice.

Investigations: Serum protein electrophoresis, contrast CT of thorax and abdomen, endoscopic retrograde cholangiopancreatography with endoscopic biopsy and pleural biopsy.

Diagnosis: Extramedullary plasmacytomas at pancreatic head and pleura.

Management: Salvage chemotherapy regimens including bortezomib plus steroid, alkylators plus steroid, bortezomib plus anthracycline and radiotherapy, and combined bortezomib, cyclophosphamide, melphalan and steroid therapy.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Boronic Acids / administration & dosage*
  • Bortezomib
  • Dose-Response Relationship, Drug
  • Drug Resistance, Neoplasm*
  • Female
  • Humans
  • Middle Aged
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / pathology
  • Pancreatic Neoplasms / drug therapy
  • Pleural Neoplasms / drug therapy
  • Protease Inhibitors / administration & dosage*
  • Pyrazines / administration & dosage*
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Boronic Acids
  • Protease Inhibitors
  • Pyrazines
  • Bortezomib